GlobalData on MSN11d
EC approves AstraZeneca’s Fasenra for EGPA treatment
Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...
PMLiVE4d
AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA
AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis ...
biopharma-reporter11d
AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
The Pharma Letter12d
EU approval for Fasenra in eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients ...
Medscape11d
Fasenra Approved in Europe for Rare Blood Vessel Disorder
The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...
ThePrint on MSN11mon
Our organs age at different rates, faster ageing means 20-50% higher mortality risk, shows study
The drug tested is known as benralizumab (SHAMAL). The multinational study, published on 7 December, was led by scientists ...
pulmonologyadvisor8d
Switching Biologics Occurs in 16% of Patients With Asthma, for Various Reasons
Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...
Pharmabiz12d
European Union approves AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
EuropaWire12d
AstraZeneca’s Fasenra Approved in EU for Treating Rare Vasculitis, Offering New Hope for EGPA Patients
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...
PharmiWeb12d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
Daily10d
AstraZeneca Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...